Article
Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma.
Current oncology (Toronto, Ont.) - 7 Apr 2021
Li Qiwen, Ma Li, Qiu Bo, Wen Yuzhi, Liang Wenhua, Hu Wanming, Chen Naibin, Zhang Tian, Xu Shuangbing, Chen Lingjuan, Guo Minzhang, Zhao Yi, Liu Songran, Guo Jinyu, Wang Junye, Wang Siyu, Wang Xin, Pang Qingsong, Long Hao, Liu Hui
Abstract excerpt
BACKGROUND: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of adjuvant TKIs with or without chemotherapy in epidermal growth factor receptor (EGFR)-mutant stage III-pN2 lung adenocarcinoma. METHODS: Two hundred and seventy-four...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.